StockTitan

@stocktitan.net

5 days ago

Lexaria to Begin New Human Clinical Study in GLP-1 Lexaria (NASDAQ:LEXX) signed contracts with a CRO to run Human Pilot Study #7 (GLP-1-H26-7) evaluating two oral DehydraTECH-semaglutide (DHT-sema) formulations versus Wegovy tablets.The 5-week, three-arm parallel study will test tablet and capsule DHT-sema with SNAC under fasted conditions, aiming to assess safety, tolerability and pharmacokinetics; ethics approval is pending and the study is fully funded from corporate resources.

#LEXX #LEXXW Lexaria to Begin New Human Clinical Study in GLP-1

www.stocktitan.net/news/LEXX/lexaria-to-beg...

StockTitan

@stocktitan.net

1 week ago

Lexaria's Robust Patent Portfolio Continues to Grow Lexaria receives 5 new patents including 2 for diabetes treatment utilizing GLP-1 drugsKELOWNA, BC / ACCESS Newswire / March 26, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this update on additional

#LEXX #LEXXW Lexaria's Robust Patent Portfolio Continues to Grow

www.stocktitan.net/news/LEXX/lexaria-s-robu...

StockTitan

@stocktitan.net

1 week ago

Lexaria's Oral GLP-1 Drug Strategy Validated by Industry Lexaria (NASDAQ:LEXX) outlines its strategy to develop oral GLP-1 capsule and tablet alternatives using its patented DehydraTECH platform, citing intellectual property established in 2024–2025 and early-stage commercial discussions with several multinational pharmaceutical companies. The company highlights market forecasts suggesting oral GLP-1s could represent a $40–45 billion annual market within four years and cites patient tolerability and discontinuation rates as drivers for its program.

#LEXX #LEXXW Lexaria's Oral GLP-1 Drug Strategy Validated by Industry

www.stocktitan.net/news/LEXX/lexaria-s-oral...

StockTitan

@stocktitan.net

1 month ago

Lexaria Announces New R&D Plans for 2026 Exciting new human and animal studies designed to enhance business opportunitiesKELOWNA, BC / ACCESS Newswire / March 4, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the beginning of its 2026 research and

#LEXX #LEXXW Lexaria Announces New R&D Plans for 2026

www.stocktitan.net/news/LEXX/lexaria-announ...

StockTitan

@stocktitan.net

2 months ago

Lexaria Awarded Six Additional Patents Lexaria (Nasdaq:LEXX) announced six newly granted patents, bringing its total to 60 granted patents across major global markets as of January 22, 2026.The six grants include: Australia (first patent) for Family #20 (sublingual nicotine); EU (first patent) for Family #21 (hypertension); two Australia and one EU patents for Family #24 (epilepsy); and one new US patent for Family #27 (diabetes), bringing that family to two US patents.Shareholders are reminded to vote at the Annual Meeting on January 27, 2026 at 1:00 PM PT.

#LEXX #LEXXW Lexaria Awarded Six Additional Patents

www.stocktitan.net/news/LEXX/lexaria-awarde...

StockTitan

@stocktitan.net

2 months ago

Lexaria Releases Annual Letter from the CEO KELOWNA, BC / ACCESS Newswire / January 12, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this Annual Letter from its Chief Executive Officer ("CEO") Richard Christopher as a strategic

#LEXX #LEXXW Lexaria Releases Annual Letter from the CEO

www.stocktitan.net/news/LEXX/lexaria-releas...

StockTitan

@stocktitan.net

3 months ago

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4 KELOWNA, BC / ACCESS Newswire / December 30, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following additional secondary and exploratory endpoint final results update on its Phase 1b, 12-week

#LEXX #LEXXW Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

www.stocktitan.net/news/LEXX/lexaria-releas...

StockTitan

@stocktitan.net

3 months ago

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4 Lexaria (Nasdaq:LEXX) announced that its Phase 1b study GLP-1-H24-4 met its primary endpoint for safety and tolerability, with DehydraTECH formulations showing lower adverse events versus the Rybelsus control.Key findings: DehydraTECH-semaglutide reduced overall side effects ~48% and gastrointestinal side effects ~55% versus Rybelsus; DHT-semaglutide showed a 47.9% reduction in total AEs versus Rybelsus. HbA1c reductions were comparable to Rybelsus (p>0.05). Rybelsus produced larger bodyweight reductions (Wk12: -5.29 kg, EOS Wk16: -4.95 kg) than DHT arms.Lexaria raised a gross $7.5 million after fiscal year-end to fund prospective 2026 development and will share the dataset with its MTA partner; the MTA was extended through April 30, 2026.

#LEXX #LEXXW Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

www.stocktitan.net/news/LEXX/primary-endpoi...

StockTitan

@stocktitan.net

4 months ago

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended Lexaria (Nasdaq:LEXX) announced an extension to its Material Transfer Agreement with a pharmaceutical company through April 30, 2026 to allow PharmaCO time to receive and review the full dataset from Lexaria's Australian human study GLP-1-H24-4.The extension keeps the temporary exclusive license active and preserves the parties' ability to continue strategic planning with PharmaCO's human clinical development team. Lexaria said initial pre-clinical pharmacokinetic animal studies under the MTA were completed earlier in 2025 and that final results from the Australian study are projected to be released before the end of Q4 2025.

#LEXX #LEXXW Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

www.stocktitan.net/news/LEXX/material-trans...

StockTitan

@stocktitan.net

5 months ago

Lexaria Bioscience Corp. Provides Strategic Update Strategic Business Development Advisory Firm Engaged To Support New Business Development ActivitiesLexaria Awarded 4 New PatentsKELOWNA, BC / ACCESS Newswire / October 9, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery

#LEXX #LEXXW Lexaria Bioscience Corp. Provides Strategic Update

www.stocktitan.net/news/LEXX/lexaria-biosci...

StockTitan

@stocktitan.net

6 months ago

5mg DehydraTECH Outperforms 15mg Rybelsus: Lexaria's Technology Enhances Brain Delivery of GLP-1 Drug Biotech firm's DehydraTECH platform demonstrates enhanced brain biodistribution of semaglutide vs. Rybelsus in rodent study. 5mg dose achieves higher brain levels than 15mg control.

#LEXX #LEXXW Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain

www.stocktitan.net/news/LEXX/lexaria-s-tech...

StockTitan

@stocktitan.net

7 months ago

Global Drug Delivery Innovator Lexaria Bioscience to Showcase at Major Investment Conference in September Lexaria Bioscience CEO Richard Christopher will present at the H.C. Wainwright Global Investment Conference Sept 8-10. Virtual presentation available from Sept 5, 7:00 AM EST.

#LEXX #LEXXW Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference

www.stocktitan.net/news/LEXX/lexaria-attend...

StockTitan

@stocktitan.net

7 months ago

Lexaria's GLP-1 Drug Shows Better Tolerability Than Rybelsus in Latest Trial Phase Phase 1b study reports fewer GI side effects compared to Rybelsus control arm. Final data analysis underway for innovative drug delivery platform. See full results.

#LEXX #LEXXW Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone

www.stocktitan.net/news/LEXX/lexaria-s-phas...

StockTitan

@stocktitan.net

8 months ago

GLP-1 "Arms Race" Broadens to Include Dozens of Companies Lexaria Bioscience (NASDAQ:LEXX) provides an update on the expanding GLP-1 and obesity drug market, highlighting its DehydraTECH technology's potential role. The market is expected to exceed $150 billion by 2030, with 39 new GLP-1 drugs in development from 34 companies.The company's DehydraTECH platform has demonstrated significant reductions in gastrointestinal adverse events across major GLP-1 drugs, showing improvements ranging from 31% to 100% in various studies. The update also details recent major industry deals, including Novo Nordisk's $2.2 billion collaboration with Septerna, Roche's $5.3 billion rights acquisition from Zealand Pharma, and Regeneron's $1.93 billion licensing deal with Hansoh Pharmaceutical.

#LEXX #LEXXW GLP-1 "Arms Race" Broadens to Include Dozens of Companies

www.stocktitan.net/news/LEXX/glp-1-arms-rac...

StockTitan

@stocktitan.net

8 months ago

Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study Lexaria Bioscience (NASDAQ:LEXX) has reported positive interim 8-week results from its Phase 1b GLP-1-H24-4 study comparing DehydraTECH-enhanced semaglutide and tirzepatide to Rybelsus®. The study revealed that DehydraTECH-semaglutide reduced overall adverse events by 36.5% and gastrointestinal side effects by 43.5% compared to Rybelsus®.Key findings show that only 79.2% of DehydraTECH-semaglutide patients experienced adverse events, compared to 100% in the Rybelsus® group. For weight loss, DehydraTECH-semaglutide showed a reduction of 1.23% after 8 weeks, while HbA1c levels decreased by 0.14%. The study is expected to complete with final results by the end of 2025.

#LEXX #LEXXW Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study

www.stocktitan.net/news/LEXX/lexaria-provid...

StockTitan

@stocktitan.net

8 months ago

Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry Lexaria Bioscience (NASDAQ:LEXX) positions its DehydraTECH technology as a potential solution for the GLP-1 industry's biggest challenge: adverse effects. The GLP-1 market is experiencing remarkable growth, with projected revenues increasing from $53.5 billion in 2024 to $70.1 billion in 2025, and expected to reach $156 billion by 2030.However, 47-64% of GLP-1 users discontinue treatment within 1-2 years, primarily due to gastrointestinal side effects. Notably, 75.7% of patients experience gastrointestinal adverse events with leading GLP-1 drugs. Lexaria's DehydraTECH technology has demonstrated in human clinical testing its ability to reduce side effects in the top three GLP-1 drugs: semaglutide, tirzepatide, and liraglutide.The company is currently collaborating with a pharmaceutical partner ("PharmaCO") under a material transfer agreement announced in September 2024 to evaluate DehydraTECH compositions.

#LEXX #LEXXW Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry

www.stocktitan.net/news/LEXX/lexaria-s-dehy...

StockTitan

@stocktitan.net

9 months ago

Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule Lexaria Bioscience (NASDAQ: LEXX) has successfully completed a human clinical study comparing oral DehydraTECH-liraglutide capsules to injectable Saxenda (liraglutide). The study demonstrated a 22.7% overall reduction in adverse events with the oral formulation, including significant decreases in nausea (67%) and gastrointestinal issues (31%). The oral version showed comparable effectiveness in blood glucose, insulin, and weight loss metrics. This breakthrough positions Lexaria to pursue FDA registration through the 505(b)(2) pathway for an oral alternative to injectable liraglutide, which generated $1.8B in revenue for Novo Nordisk in 2024. Notably, Lexaria has now shown reduced adverse events with DehydraTECH versions of all three major GLP-1 drugs: liraglutide, semaglutide, and tirzepatide.

#LEXX #LEXXW Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule

www.stocktitan.net/news/LEXX/lexaria-s-dehy...

StockTitan

@stocktitan.net

10 months ago

Lexaria Targets Weight Loss and Diabetes Partnerships at Massive BIO Convention with 20,000 Attendees Lexaria executives schedule partnership meetings at BIO 2025 to advance DehydraTECH drug delivery platform in weight loss, diabetes, and hypertension. Learn more.

#LEXX #LEXXW Lexaria Attending BIO International Convention

www.stocktitan.net/news/LEXX/lexaria-attend...

StockTitan

@stocktitan.net

10 months ago

Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company Lexaria Bioscience Corp. (NASDAQ: LEXX) has provided an update on its Material Transfer Agreement (MTA) with an unnamed pharmaceutical company (PharmaCO). The company has completed initial pre-clinical pharmacokinetic animal studies evaluating Lexaria's DehydraTECHTM technology, though results will remain confidential. PharmaCO has expressed interest in reviewing pending safety and efficacy data from Lexaria's ongoing independent human study GLP-1-H24-4 in Australia, expected in Q3 2025.Lexaria is preparing for strategic planning discussions with PharmaCO's human clinical development team regarding potential collaborative human clinical studies. Both parties have agreed to maintain their relationship and keep the temporary exclusive license active until the Australian study data becomes available.

#LEXX #LEXXW Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company

www.stocktitan.net/news/LEXX/lexaria-provid...

StockTitan

@stocktitan.net

1 year ago

Lexaria's GLP-1 Study Hits Major Milestone with 20% Higher Patient Enrollment Latest milestone: Phase 1b GLP-1 study exceeds recruitment targets by 20%. Results expected after 12-week treatment period. Full analysis inside.

#LEXX #LEXXW Lexaria Updates its Ongoing Human Study GLP-1-H24-4

www.stocktitan.net/news/LEXX/lexaria-update...

StockTitan

@stocktitan.net

1 year ago

Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R) Lexaria Bioscience (NASDAQ:LEXX) announced positive results from Human Study #3 comparing oral DehydraTECH-tirzepatide capsules to injectable Zepbound®. The study showed that oral capsules achieved comparable blood concentration levels to injections by the study's end.Key findings from the 8-day study of 19 participants revealed that while injected Zepbound® typically peaked on Day 2 and declined, DehydraTECH-tirzepatide levels increased steadily daily. The oral version demonstrated:47% fewer adverse events (20 vs 38)54% reduction in gastrointestinal side effectsSimilar blood glucose reduction and insulin increase by Day 8The company is now conducting a 12-week Phase 1b registrational study in Australia, starting at 20mg/day for 4 weeks and escalating to 40mg/day for the remaining 8 weeks. This extended study aims to evaluate steady-state blood levels and potentially demonstrate increased delivery and efficacy.

#LEXX #LEXXW Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R)

www.stocktitan.net/news/LEXX/lexaria-s-dehy...

StockTitan

@stocktitan.net

1 year ago

Could This Small Biotech Solve GLP-1 Drugs' Biggest Problems? Lexaria's Triple Strategy Explained Lexaria's DehydraTECH technology shows superior delivery to Rybelsus and reduced side effects for GLP-1 drugs in a market projected to reach $471B.

#LEXX #LEXXW The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

www.stocktitan.net/news/LEXX/the-global-rev...

StockTitan

@stocktitan.net

1 year ago

Can This Small Biotech Transform GLP-1 Drugs From Shots to Pills? Clinical Trial Update Final ethics approval received for comprehensive GLP-1 study testing oral delivery of both semaglutide and tirzepatide, with first dosing already underway.

#LEXX #LEXXW Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

www.stocktitan.net/news/LEXX/ethics-board-a...

StockTitan

@stocktitan.net

1 year ago

Can This Small Biotech Revolutionize $30B GLP-1 Market With First-Ever Oral Liraglutide? DehydraTECH oral technology shows 11.5% better blood sugar control than Rybelsus, targeting $30B GLP-1 market dominated by injectable drugs

#LEXX #LEXXW Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide

www.stocktitan.net/news/LEXX/lexaria-s-stra...

StockTitan

@stocktitan.net

1 year ago

Lexaria's Game-Changing Epilepsy Patents Outperform Epidiolex Technology | LEXX Lexaria expands patent portfolio with two USPTO grants for DehydraTECH epilepsy treatment, showing superior absorption vs Epidiolex. Protection extends to 2043.

#LEXX #LEXXW Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy

www.stocktitan.net/news/LEXX/lexaria-grante...

StockTitan

@stocktitan.net

1 year ago

Revolutionary GLP-1 Study: Lexaria's DehydraTECH Goes Head-to-Head with Rybelsus Lexaria initiates groundbreaking biodistribution study comparing DehydraTECH-processed semaglutide against Rybelsus, tracking effectiveness across major organs using fluorescent technology.

#LEXX #LEXXW Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway

www.stocktitan.net/news/LEXX/lexaria-biodis...

StockTitan

@stocktitan.net

1 year ago

Revolutionary GLP-1 Breakthrough: Lexaria's Technology Matches Zepbound Efficacy with Fewer Side Effects Lexaria advances Phase 1b study with new DehydraTECH-tirzepatide arm following successful pilot showing comparable glucose control and reduced side effects vs Zepbound®.

#LEXX #LEXXW Lexaria Updates its Ongoing Human Study GLP-1-H24-4

www.stocktitan.net/news/LEXX/lexaria-update...

StockTitan

@stocktitan.net

1 year ago

Lexaria Releases Annual Letter from the CEO Lexaria Bioscience (NASDAQ:LEXX) released its annual CEO letter highlighting significant achievements in 2024, particularly in GLP-1 drug delivery technology. The company raised $13.4M net through equity raises and warrant exercises, while its stock price increased 68% during the year.Key developments included successful completion of multiple studies demonstrating positive results with DehydraTECH technology for GLP-1 drugs: semaglutide, tirzepatide, and liraglutide. Notable outcomes included 18.8% higher semaglutide levels and 60% reduction in adverse events compared to Rybelsus®.The company launched its first Phase 1b registrational study in Australia and received FDA clearance for a Phase 1b hypertension study. Lexaria secured 8 additional patents, expanding its portfolio to 46 patents worldwide, and entered into a Material Transfer Agreement with a pharmaceutical company for pre-clinical evaluation of DehydraTECH technology.

#LEXX #LEXXW Lexaria Releases Annual Letter from the CEO

www.stocktitan.net/news/LEXX/lexaria-releas...

StockTitan

@stocktitan.net

1 year ago

Lexaria Gets Green Light for Oral Weight Loss Drug Trial, Aims to Replace Saxenda Injections Lexaria advances with human trials for oral DehydraTECH-liraglutide after promising animal results showed 5.88% weight loss. Could revolutionize $2B+ injectable GLP-1 market.

#LEXX #LEXXW Lexaria’s Human GLP-1 Study #5 Receives Independent Review Board Approval

www.stocktitan.net/news/LEXX/lexaria-s-huma...

StockTitan

@stocktitan.net

1 year ago

Lexaria's Oral GLP-1 Drug Shows 47% Fewer Side Effects Than Injectable Zepbound in Clinical Study Lexaria's DehydraTECH-tirzepatide demonstrates comparable efficacy to injectable Zepbound with significantly reduced adverse events. Study shows promising glucose control results.

#LEXX #LEXXW Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)

www.stocktitan.net/news/LEXX/lexaria-s-oral...